Lobbying

Lilly USA's latest lobbying report covers Q2 2023, at $60K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Lilly USA

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Lilly USA lobbying by quarter
Lilly USA lobbying by quarter
QuarterAmountReports
Q4 2022$60K1
Q1 2023$60K1
Q2 2023$60K1
Q3 2023$00
Q4 2023$00
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$90K · 3 reports
  • Medicare and Medicaid$90K · 3 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES3 reports
  • SENATE3 reports

Firms it paid

Firm
Crossroads Strategies$180K3 quarters

Former officials lobbying for it

Former position
CHERYL LYNN JAEGERShared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. CoxQ2 2023

Lobbying reports

Filed by
23/07/20for Q2 2023Crossroads Strategies$60K
23/04/19for Q1 2023Crossroads Strategies$60K
23/01/20for Q4 2022Crossroads Strategies$60K